BioArctic: FDA approves IV maintenance dosing of Leqembi (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's ...
Biogen Inc.: FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...
Hosted on MSN9h
New technology enables smartwatches to detect depression
The pressures of modern living, including shift work and irregular schedules, are disrupting natural circadian rhythms. This ...
Knowridge15h
Xenon gas is a novel approach to Alzheimer’s treatment
A groundbreaking study by researchers from Mass General Brigham and Washington University School of Medicine in St. Louis has ...
Journal of Medical Internet Research21h
Journal of Medical Internet Research
Current diagnostic methods, including clinical assessments and laboratory tests, frequently lack the speed and specificity needed for timely intervention, particularly in vulnerable populations such ...